Amgen Inc. $AMGN Shares Sold by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 5.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,695 shares of the medical research company’s stock after selling 2,738 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Amgen were worth $14,306,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Brighton Jones LLC boosted its stake in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares in the last quarter. McAdam LLC boosted its stake in Amgen by 61.2% during the 2nd quarter. McAdam LLC now owns 1,394 shares of the medical research company’s stock worth $389,000 after purchasing an additional 529 shares during the last quarter. Plancorp LLC grew its holdings in shares of Amgen by 2.7% during the second quarter. Plancorp LLC now owns 3,156 shares of the medical research company’s stock worth $881,000 after buying an additional 84 shares in the last quarter. Finally, Magnus Financial Group LLC raised its position in shares of Amgen by 20.1% in the second quarter. Magnus Financial Group LLC now owns 1,453 shares of the medical research company’s stock valued at $406,000 after buying an additional 243 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Down 0.7%

AMGN opened at $344.75 on Friday. The stock has a market capitalization of $185.64 billion, a PE ratio of 26.64, a P/E/G ratio of 3.09 and a beta of 0.45. Amgen Inc. has a one year low of $261.43 and a one year high of $349.98. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. The business’s 50 day moving average price is $332.07 and its 200 day moving average price is $307.54.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter in the previous year, the business earned $5.58 earnings per share. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s dividend payout ratio is currently 77.90%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a dividend increase to $2.52, reinforcing its income profile and making the stock more attractive to dividend-focused investors. This supports longer-term investor demand. Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.52
• Positive Sentiment: Amgen expanded its obesity/GLP‑1 strategy via a collaboration with Ro, signaling potential new mid-term revenue streams if programs progress. Pipeline progress tends to boost investor sentiment for growth prospects. Amgen (AMGN) expands obesity strategy with Ro collaboration on GLP-1 therapies
• Positive Sentiment: The stock recently hit a 52-week high, reflecting recent buyer interest and validation of recent corporate moves and sentiment around the pipeline. Amgen stock hits 52-week high at $346.41
• Neutral Sentiment: Zacks notes AMGN is a trending stock on its platform, outlining investor attention and search interest but providing no new catalyst; useful context on market interest but not a direct driver. Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
• Neutral Sentiment: Analyst commentary and deep-dive pieces (e.g., Seeking Alpha on MariTide obesity/T2D potential) highlight upside from R&D, but these are longer‑horizon, research-driven views rather than immediate catalysts. Amgen: A Buy In 2026 On Exciting MariTide Obesity – T2D Potential
• Negative Sentiment: Sagebrush has sued Amgen over disputes tied to the 340B program, introducing legal, reimbursement and stakeholder-risk that could pressure margins or create uncertainty around commercial terms. Litigation and policy disputes can weigh on near-term sentiment. Sagebrush sues Amgen over 340B program row
• Negative Sentiment: Sanford C. Bernstein downgraded Amgen to a Hold / lowered its rating, which can trigger selling or reduced conviction among institutional investors and contribute to downward pressure. Bernstein downgrades Amgen (AMGN) to a Hold

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the sale, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 10,908 shares of company stock valued at $3,674,966 over the last 90 days. 0.76% of the stock is owned by company insiders.

Analyst Ratings Changes

AMGN has been the topic of a number of recent research reports. UBS Group upgraded shares of Amgen to a “strong-buy” rating in a research report on Wednesday, January 7th. Piper Sandler boosted their target price on Amgen from $342.00 to $381.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Guggenheim increased their price target on Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. HSBC reiterated a “buy” rating and set a $425.00 price objective on shares of Amgen in a research report on Wednesday, December 10th. Finally, Royal Bank Of Canada upped their target price on Amgen from $330.00 to $335.00 and gave the company an “outperform” rating in a report on Thursday, January 8th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and an average target price of $339.24.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.